← Leaderboards
Anthony James Hickey
University Of North Carolina Chapel Hill
$6,940,027
Attributed
$10,968,516
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–22$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$10,968,516 · 6
By mechanism
R01$10,466,741 · 5
R21$501,775 · 1
Top collaborators
- Miriam S. Braunstein7 shared
- Mercedes Gonzalez-Juarrero7 shared
- Bernd Meibohm7 shared
Others in their field
Top investigators on “Aerosols”
- Kimberly A Prather · University Of California-Riverside$46,542,272
- Thomas Gary Ksiazek · University Of Texas Med Br Galveston$32,195,929
- Jeffery Dill · Battelle Centers/Pub Hlth Res & Evaluatn$30,023,104
- Barton F Haynes · Duke University$27,999,998
- Charles L Bailey · George Mason University$27,475,000
- Deepak Kaushal · University Of Chicago$26,419,545
Research focus
AerosolsDoseDrug KineticsPharmaceutical PreparationsLungRouteTuberculosisMycobacterium TuberculosisTuberculosis TreatmentCaviaInfectionSafetyAnimal ModelOrganSubcutaneousRegimenMulti-Drug ResistanceIn VivoPowder Dose FormToxic EffectParticleAnimalsExtreme Drug Resistant TuberculosisMultidrug-Resistant Tuberculosis
Grant awards (19)
Inhaled tigecycline therapy for pulmonary M. abscessus infections$794,098
R01 · FY2022 · AI
Development of Inhaled CPZEN-45 For Tuberculosis Therapy$1,483,617
R01 · FY2021 · AI · contact PI
Inhaled tigecycline therapy for pulmonary M. abscessus infections$836,428
R01 · FY2021 · AI
Development of Inhaled CPZEN-45 For Tuberculosis Therapy$756,053
R01 · FY2020 · AI · contact PI
Aerosol spectinamide-1599 therapy against tuberculosis$710,674
R01 · FY2020 · AI
Development of Inhaled CPZEN-45 For Tuberculosis Therapy$1,006,759
R01 · FY2019 · AI · contact PI
Aerosol spectinamide-1599 therapy against tuberculosis$729,832
R01 · FY2019 · AI
Aerosol spectinamide-1599 therapy against tuberculosis$668,501
R01 · FY2018 · AI
Inhaled pyrazinoic acid for tuberculosis therapy$220,013
R21 · FY2018 · AI
Aerosol spectinamide-1599 therapy against tuberculosis$848,545
R01 · FY2017 · AI
Inhaled pyrazinoic acid for tuberculosis therapy$281,762
R21 · FY2017 · AI
Aerosol spectinamide-1599 therapy against tuberculosis$629,894
R01 · FY2016 · AI
Inhaled Caprazamycin for Tuberculolsis Therapy$356,973
R01 · FY2013 · AI · contact PI
Inhaled Caprazamycin for Tuberculolsis Therapy$332,768
R01 · FY2012 · AI · contact PI
Inhaled Caprazamycin for Tuberculolsis Therapy$266,824
R01 · FY2011 · AI · contact PI
MECHANISMS OF RESPONSE TO PULMONARY VACCINATION$254,625
R01 · FY2005 · HL
MECHANISMS OF RESPONSE TO PULMONARY VACCINATION$254,625
R01 · FY2004 · HL
MECHANISMS OF RESPONSE TO PULMONARY VACCINATION$254,625
R01 · FY2003 · HL
MECHANISMS OF RESPONSE TO PULMONARY VACCINATION$281,900
R01 · FY2002 · HL